Slide 1: Investor Presentation April 28, 2016
Ticker: MRIC Investor Presentation April 28, 2016 Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 1
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements often can be identified by words such as “an
Slide 3: MRI Interventions Opportunity
MRI Interventions Opportunity o Market potential Market Potential o 55,000 potential ClearPoint procedures across multiple therapies o Electrode placement for deep brain stimulation Navigation System o Laser Ablation for ablation of epileptic foci or Brain Tumors for Multiple Therapies o Brain Tumor
Slide 4: MRI Interventions: Real Time MRI Guided Surgery
MRI Interventions: Real Time MRI Guided Surgery First-to-market technology platform enabling real-time MRI guided surgery; FDA-cleared, CE-marked and 40+ ClearPoint sites Focused commercialization of neuro platform underway; recent restructuring complete Attractive razor/razorblade business model wi
Slide 5: Leadership - A History of Med Device Experience
Leadership - A History of Med Device Experience Key Management Executive Title Prior Experience Frank Grillo President, CEO Peter Piferi COO Wendelin Maners VP Marketing Robert Korn VP Sales Hal Hurwitz CFO Board of Directors Kimble Jenkins, Maria Sainz Dr. Phillip Pizzo Pascal Girin Timothy Frank G
Slide 6: Technology: ClearPoint Neuro Navigation System
Technology: ClearPoint® Neuro Navigation System Navigation System consisting of Integrated Devices and Software for Real-Time, MRI Guided, Minimally Invasive Neurosurgical Procedures Visualize Verify Confirm o Identify target o Observe progress to target o Confirm precise placement at target © 2016
Slide 7: Without ClearPoint, minimally invasive neuro procedures are performed blind
Without ClearPoint, minimally invasive neuro procedures are performed “blind” Conventional Stereotactic Procedure ClearPoint Neuro Procedure No real-time visualization Next generation platform enabling real-time, MRI-guided, minimally invasive brain surgery © 2016 MRI INTERVENTIONS, INC. | 7
Slide 8: ClearPoint Neuro Navigation System
ClearPoint® Neuro Navigation System 1.5T or 3T MR Scanners, also works in intraop MRI Suites MRI Safe Disposable Components: SmartGrid® and SmartFrame® -Integrated ClearPoint Targeting and Trajectory Precision ClearPoint® Drape provides sterile procedural field in any diagnostic or intraoperative MR
Slide 9: ClearPoint Procedure Overview: Target Selection & Entry Planning
ClearPoint Procedure Overview Target Selection & Entry Planning © 2016 MRI INTERVENTIONS, INC. | 9
Slide 10: ClearPoint Procedure Overview: Trajectory Alignment & Device Insertion
ClearPoint Procedure Overview SmartFrame® Trajectory Guide Trajectory Alignment & Device Insertion SmartFrame® Hand Controller © 2016 MRI INTERVENTIONS, INC. | 10
Slide 11: ClearPoint Procedure Overview: Delivery of Neurological Therapy
ClearPoint Procedure Overview Delivery of Neurological Therapy (1) Drug Delivery - The SmartFlow® cannula received 510(k) clearance for injection of cytarabine, a chemotherapy drug, to the ventricles or removal of CSF from the ventricles during intracranial procedures. Delivery of other therapeutic
Slide 12: ClearPoint Hospital Economics
ClearPoint Hospital Economics Increase Patients o Better potential patient experience provides hospitals the opportunity to reach additional patient populations that may otherwise forego surgery o 65% of eligible DBS patients refuse treatment, due to fear of surgery(1) Established, Attractive Reimbu
Slide 13: Multi-Therapy MRI-Guided Navigational System
Multi-Therapy MRI-Guided Navigational System Notable Neurosurgeon Supporters Dr. Philip Starr Dr. Paul Larson Dr. Robert Gross Dr. Robert Wharen, Jr. Dr. Krys Bankiewicz Dr. Russ Lonser ASSFN Past President UCSF & VA Emory University Mayo Clinic - Bankiewicz Lab, UCSF OSU - NIH Jacksonville Publishe
Slide 14: Patented Intellectual Property
Patented Intellectual Property Close to 100 issued patents around the world 30+ U.S. 50+ OUS 70+ U.S. Patents 45+ OUS Patents Patent Applications Patent Applications o Issued patents cover areas such as: MRI-guided surgical systems that include software and devices; the SmartFrame® trajectory guide;
Slide 15: Patient Impact: Martin's Story
Patient Impact M a r t i n’s S t o r y C l e a r Po i n t - E n a b l e d E l e c t r o d e P l a c e m e n t © 2016 MRI INTERVENTIONS, INC. | 15
Slide 16: Patient Benefit - Minimally Invasive Procedure
Patient Benefit - Minimally Invasive Procedure 7 days after ClearPoint procedure - Arrow Indicates Surgery Site © 2016 MRI INTERVENTIONS, INC. | 16
Slide 17: ClearPoint Drug Delivery
ClearPoint Drug Delivery o MR visualization of neuro target o MR-guided placement of catheter o Therapeutic agent delivered under MR-guidance* Specialized drug delivery cannula’s / catheters Conclusion: The ClearPoint system allows Real-time Convection-enhanced Delivery to be performed with a high l
Slide 18: MRIC's Unique Opportunity for Drug Delivery
MRIC’s Unique Opportunity for Drug Delivery Major Challenges in Delivering Drugs to the Brain - Blood brain barrier blocks systemic delivery of almost all drugs - up to 98% of small molecules - Direct injection without ClearPoint is blind, so target can frequently be missed - Neopharm Trial - 51% of
Slide 19: The ClearPoint Difference
The ClearPoint Difference Without ClearPoint (Stereotactic) With ClearPoint No direct visualization; Performed in an operating Direct, high resolution visualization; Performed in room an MRI Suite Accuracy to target based on prior images Highly accurate, based on real time images Patient may be awak
Slide 20: ClearPoint Revenue Model
ClearPoint Revenue Model B U S I N E S S M O D E L - R A Z O R / R A Z O R B L A D E ??ClearPoint Hardware/Software: $100,000 - $150,000 ASP ??ClearPoint Disposables: $7,500 (average) ASP per procedure with potentially strong margins??Recurring revenue from the sale of disposables??Procedures covere
Slide 21: Growing the ClearPoint Footprint
Growing the ClearPoint Footprint Installed Base of 45 sites in the US Europe: Warsaw, Poland © 2016 MRI INTERVENTIONS, INC. | 21
Slide 22: ClearPoint US Market Opportunity
ClearPoint US Market Opportunity Parkinson’s Epilepsy Brain Tumors Total Prevalence (US) 1,500,000 2,200,000 80,000 (annual diagnosis) Prevalence - Drug Treatment 125,000 264,000 Resistant (DTR) 7,500 18,000 Resections: 80,000 Incidence - DTR Stereotactic Biopsy: 10,000 Electrode Laser Ablation Biop
Slide 23: ClearPoint Future Opportunities
ClearPoint Future Opportunities Multiple Therapies for Future Growth Patient Treatment Resistant ClearPoint Enabled Current Status Neuro Disorder Population Patient Population Therapy Dystonia 250,000 25,000 DBS Active Use, HDE OCD 3,300,300 100,000 DBS Active Use, HDE Severe Depression 6,000,000 1,
Slide 24: ClearPoint Consumable Revenues
ClearPoint Consumable Revenues Consumables $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 | 24
Slide 25: Total Revenue, 2013 - 2015
Total Revenue, 2013 - 2015 $1,600,000 Total Revenue $1,400,000 $1,200,000 $1,000,000 $800,000 $600,000 $400,000 $200,000 $- Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 2016 Consumables Capital / Service Other © 2016 MRI INTERVENTIONS, INC. | 25
Slide 26: Cash Flow From Operations
Cash Flow From Operations $0 -$500,000 -$1,000,000 -$1,500,000 -$2,000,000 -$2,500,000 -$3,000,000 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2014 2015 2016 © 2016 MRI INTERVENTIONS, INC. | 26
Slide 27: Commercial Priorities
Commercial Priorities o Focus on adding surgeons at existing accounts Increase o Target high volume sites, including epilepsy and tumor neurosurgeons within each Utilization account; gain greater share of their procedures o Add Clinical Specialists and sales reps to commercial team; compensate for u
Slide 28: At the Center of an Emerging Industry Trend
At the Center of an Emerging Industry Trend ClearPoint ClearPoint MRIC is at the point of Electrode Laser Catheter Placement Placement convergence in an industry trend impacting Real Time MRI- some of the most ClearPoint Guided ClearPoint Direct Drug Procedures Performed influential and Delivery in
Slide 29: MRI Interventions, Inc.
Ticker: MRIC MRI Interventions, Inc. Irvine, CA 949.900.6833 mriinterventions.com Transforming minimally invasive neurosurgery by enabling real-time visualization with MRI © 2016 MRI INTERVENTIONS, INC. | 29